Various Applications of Tofacitinib and Ruxolitinib (Janus Kinase Inhibitors) in Dermatology and Rheumatology: A Review of Current Evidence and Future Perspective
Backgrounds: Janus kinase inhibitors (JAKi) are anti-inflammatory medications suppressing Janus kinase-signal transducer and activator of transcription (JAK-STAT) pathway by inhibiting various cytokines receptors on the membrane of cells. Mutations and polymorphisms on JAK and STAT proteins can cau...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Mattioli1885
2022-10-01
|
| Series: | Dermatology Practical & Conceptual |
| Subjects: | |
| Online Access: | https://www.dpcj.org/index.php/dpc/article/view/2201 |